MA57574A1 - Utilisation d'un composé nucléoside dans le traitement des maladies infectieuses à coronavirus - Google Patents

Utilisation d'un composé nucléoside dans le traitement des maladies infectieuses à coronavirus

Info

Publication number
MA57574A1
MA57574A1 MA57574A MA57574A MA57574A1 MA 57574 A1 MA57574 A1 MA 57574A1 MA 57574 A MA57574 A MA 57574A MA 57574 A MA57574 A MA 57574A MA 57574 A1 MA57574 A1 MA 57574A1
Authority
MA
Morocco
Prior art keywords
infectious diseases
treatment
nucleoside compound
coronavirus
coronavirus infectious
Prior art date
Application number
MA57574A
Other languages
English (en)
Inventor
Junbiao Chang
Jinfa Du
Jiandong Jiang
Yuhuan Li
Original Assignee
Henan Genuine Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henan Genuine Biotech Co Ltd filed Critical Henan Genuine Biotech Co Ltd
Publication of MA57574A1 publication Critical patent/MA57574A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention concerne l'utilisation d'un composé représenté par la formule (i) ou de ses sels pharmaceutiquement acceptables dans la préparation de médicaments pour prévenir ou traiter les maladies infectieuses à coronavirus. Le composé représenté par la formule (i) est utilisé pour traiter les patients atteints d'une pneumonie causée par un nouveau coronavirus, et présente des avantages évidents en ce qui concerne le rapport de conversion négative du test d'acide nucléique viral, le cours de conversion négative et le temps de guérison et de sortie de l'hôpital.
MA57574A 2020-02-27 2021-02-20 Utilisation d'un composé nucléoside dans le traitement des maladies infectieuses à coronavirus MA57574A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010125799.2A CN113304166B (zh) 2020-02-27 2020-02-27 核苷类化合物在制备治疗冠状病毒感染性疾病的药物中的用途
PCT/CN2021/077010 WO2021169861A1 (fr) 2020-02-27 2021-02-20 Utilisation d'un composé nucléoside dans le traitement des maladies infectieuses à coronavirus

Publications (1)

Publication Number Publication Date
MA57574A1 true MA57574A1 (fr) 2023-11-30

Family

ID=77370412

Family Applications (1)

Application Number Title Priority Date Filing Date
MA57574A MA57574A1 (fr) 2020-02-27 2021-02-20 Utilisation d'un composé nucléoside dans le traitement des maladies infectieuses à coronavirus

Country Status (13)

Country Link
US (1) US20230277576A1 (fr)
EP (1) EP4112050A4 (fr)
JP (1) JP2023516628A (fr)
KR (1) KR20220146496A (fr)
CN (2) CN113304166B (fr)
AU (1) AU2021228008A1 (fr)
BR (1) BR112022017209A2 (fr)
CA (1) CA3167927A1 (fr)
IL (1) IL295840A (fr)
MA (1) MA57574A1 (fr)
MX (1) MX2022010248A (fr)
WO (1) WO2021169861A1 (fr)
ZA (1) ZA202210636B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114288313B (zh) * 2022-02-18 2023-07-04 常晓宇 嘧啶核苷类药物在制备预防或治疗冠状病毒感染性疾病药物中的用途
CN118021821A (zh) * 2022-03-03 2024-05-14 苏州旺山旺水生物医药股份有限公司 治疗、预防由病毒感染引起的相关疾病的药物及其用途
CN117982522A (zh) * 2022-11-02 2024-05-07 河南真实生物科技有限公司 核苷类化合物的制药用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1425022A4 (fr) * 2001-08-24 2009-04-29 Koronis Pharmaceuticals Inc Analogues de nucleoside mutagene pour le traitement d'une maladie virale
US20040259934A1 (en) * 2003-05-01 2004-12-23 Olsen David B. Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
CN100398555C (zh) * 2003-05-06 2008-07-02 西托维亚公司 冠状病毒和sars-cov的蛋白酶抑制剂及其应用
WO2005020885A2 (fr) * 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions et methodes pour le traitement du syndrome respiratoire aigu severe (sras)
CN1237185C (zh) * 2003-06-04 2006-01-18 中国科学院上海药物研究所 Sars冠状病毒3cl蛋白酶三维结构模型与抗sars药物
CN109890808B (zh) * 2016-08-19 2020-08-07 吉利德科学公司 用于预防性或治疗性治疗hiv病毒感染的治疗性化合物
US20190185509A1 (en) * 2017-12-20 2019-06-20 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'2' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
JP7083398B2 (ja) * 2018-02-15 2022-06-10 ギリアード サイエンシーズ， インコーポレイテッド ピリジン誘導体およびｈｉｖ感染を処置するためのその使用
TWI766172B (zh) * 2018-07-30 2022-06-01 美商基利科學股份有限公司 抗hiv化合物

Also Published As

Publication number Publication date
ZA202210636B (en) 2024-01-31
EP4112050A4 (fr) 2024-03-20
AU2021228008A1 (en) 2022-09-22
BR112022017209A2 (pt) 2022-10-11
EP4112050A1 (fr) 2023-01-04
IL295840A (en) 2022-10-01
CA3167927A1 (fr) 2021-09-02
US20230277576A1 (en) 2023-09-07
WO2021169861A1 (fr) 2021-09-02
CN113304166A (zh) 2021-08-27
JP2023516628A (ja) 2023-04-20
CN113304166B (zh) 2022-10-14
CN116098917A (zh) 2023-05-12
KR20220146496A (ko) 2022-11-01
MX2022010248A (es) 2022-10-10

Similar Documents

Publication Publication Date Title
MA56074B1 (fr) Anticorps contre le sars-cov-2
MA57574A1 (fr) Utilisation d'un composé nucléoside dans le traitement des maladies infectieuses à coronavirus
RU2007119390A (ru) Соединения 4-метоксиметил-пирролидин-2-карбоновой кислоты и их производные - ингибиторы вируса гепатита с
EA200200471A1 (ru) Конденсированные нафтиридины в качестве ингибиторов обратной транскриптазы вич
RU2011127080A (ru) Производное циклоспорина для применения в лечении заражения вирусом гепатита с и вич
Ruprecht et al. Interferon-α and 3′-azido-3′-deoxythymidine are highly synergistic in mice and prevent viremia after acute retrovirus exposure
CN108640959B (zh) 3’-脱氧-3’,4’-二脱氢核苷类化合物及其应用
Lam et al. Herpes simplex infection in acute myelogenous leukemia and other hematologic malignancies: a prospective study
López-Estebaranz et al. Febrile ulceronecrotic Mucha-Habermann disease
Furukawa et al. Distribution of human papillomavirus genotype in anal condyloma acuminatum among Japanese men: the higher prevalence of high risk human papillomavirus in men who have sex with men with HIV infection
US5519028A (en) Antiviral preparations
BE903675Q (fr) Compositions contenant des 1,2,4-triazole-3-carboxamides et leur methode d'utilisation
JP2004083576A (ja) Ｈｉｖ感受性株に対して活性をもち、ヌクレオシド系ならびに非ヌクレオシド系の逆転写酵素阻害剤、およびプロテアーゼ阻害剤に対し抵抗性のｈｉｖ株に対して活性をもつ抗レトロウイルス治療薬を得るための、クロロキン、ヒドロキシクロロキン、および４アミノ−キノリン酸誘導体の使用
McCullough et al. Human immunodeficiency virus infection: a review of the mode of infection, pathogenesis, disease course, and the general and clinical manifestations
Massari et al. Polyarteritis nodosa and HIV infection: no evidence of a direct pathogenic role of HIV
CN113288892A (zh) 聚adp核糖聚合酶抑制剂在抗冠状病毒中的应用
US3423508A (en) Method of combatting herpes virus with 5-nitrouracil
KR102405447B1 (ko) 5-(2-아마노에틸)-디벤조[cd,f]-인돌-4(5H)-온 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 포함하는 항 HIV-1용 약학적 조성물
NO951608L (no) Anvendelse av BHAP-forbindelser i kombinasjon med andre ikke-nukleoside reverstranskriptaseinhibitorer for behandling av HIV-infeksjon
Patro et al. A9 A method to obtain full-length HIV proviral sequences and their sites of integration
Cleveland et al. Hypersensitivity to IV Ustekinumab but Tolerance to Subcutaneous Ustekinumab in a Patient With Crohn's Disease: 2047
Heffner et al. Abdominal hemorrhage after perforation of a diaphragmatic artery during thoracentesis
Dianzani et al. The number of HIV DNA-infected mononuclear cells is reduced under HAART plus recombinant IL-2
González Domenech et al. A8 Epidemiological study of transmission clusters in a local HIV-1 cohort
Barnett Recurrent Attacks of General Paresis after 12 and 18 Years